Kura Oncology, Inc. NASDAQ:KURA

Kura Oncology stock price today

$7.33
-1.33
-15.46%
Financial Health
0
1
2
3
4
5
6
7
8
9

Kura Oncology stock price monthly change

-61.28%
month

Kura Oncology stock price quarterly change

-61.28%
quarter

Kura Oncology stock price yearly change

-38.99%
year

Kura Oncology key metrics

Market Cap
686.65M
Enterprise value
772.88M
P/E
-6.07
EV/Sales
N/A
EV/EBITDA
-5.81
Price/Sales
N/A
Price/Book
1.92
PEG ratio
1.99
EPS
-2.17
Revenue
N/A
EBITDA
-178.75M
Income
-168.08M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Kura Oncology stock price history

Kura Oncology stock forecast

Kura Oncology financial statements

Average Price Target
Last Year

$19

Potential upside: 159.20%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Kura Oncology, Inc. (NASDAQ:KURA): Profit margin
Jun 2023 0 -37.17M
Sep 2023 0 -38.60M
Dec 2023 1.27M -42.78M -3368.98%
Mar 2024 0 -49.52M
Kura Oncology, Inc. (NASDAQ:KURA): Debt to assets
Jun 2023 494737000 11.16M 2.26%
Sep 2023 473771000 43.83M 9.25%
Dec 2023 448935000 51.66M 11.51%
Mar 2024 553908000 48.82M 8.81%
Kura Oncology, Inc. (NASDAQ:KURA): Cash Flow
Jun 2023 -25.61M -46.32M 94.00M
Sep 2023 -29.02M 8.55M 84K
Dec 2023 -34.30M 42.19M 691K
Mar 2024 -48.84M -95.33M 148.36M

Kura Oncology alternative data

Kura Oncology, Inc. (NASDAQ:KURA): Employee count
Aug 2023 131
Sep 2023 133
Oct 2023 133
Nov 2023 133
Dec 2023 131
Jan 2024 131
Feb 2024 131
Mar 2024 142
Apr 2024 142
May 2024 142
Jun 2024 142
Jul 2024 142

Kura Oncology other data

100.00% +3.47%
of KURA is owned by hedge funds
66.62M +2.57M
shares is hold by hedge funds

Kura Oncology, Inc. (NASDAQ:KURA): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 101957
May 2024 0 2615
Nov 2024 0 526
Transaction Date Insider Security Shares Price per share Total value Source
Sale
FORD KATHLEEN officer: Chief Op.. Common Stock 526 $16.03 $8,434
Sale
BAIR TERESA BROPHY officer: Chief Legal Officer
Common Stock 2,615 $22.15 $57,917
Sale
DALE STEPHEN officer: Chief Me.. Common Stock 4,825 $21.55 $103,979
Sale
DOYLE THOMAS JAMES officer: SVP, Finance & Account..
Common Stock 594 $17.8 $10,574
Sale
DOYLE THOMAS JAMES officer: SVP, Finance & Account..
Common Stock 761 $17.8 $13,547
Sale
DOYLE THOMAS JAMES officer: SVP, Finance & Account..
Common Stock 963 $17.8 $17,142
Sale
BAIR TERESA BROPHY officer: Chief Legal Officer
Common Stock 2,053 $17.8 $36,545
Sale
FORD KATHLEEN officer: Chief Op.. Common Stock 1,496 $17.8 $26,630
Sale
DALE STEPHEN officer: Chief Me.. Common Stock 4,400 $17.8 $78,324
Sale
DALE STEPHEN officer: Chief Me.. Common Stock 2,758 $17.8 $49,095
Patent
Application
Filling date: 26 Mar 2020 Issue date: 2 Jun 2022
Application
Filling date: 12 Mar 2020 Issue date: 12 May 2022
Application
Filling date: 28 Feb 2020 Issue date: 12 May 2022
Application
Filling date: 28 Sep 2021 Issue date: 21 Apr 2022
Application
Filling date: 20 Dec 2019 Issue date: 10 Mar 2022
Application
Filling date: 31 Oct 2019 Issue date: 6 Jan 2022
Grant
Filling date: 13 Jun 2018 Issue date: 28 Dec 2021
Application
Filling date: 17 Aug 2021 Issue date: 9 Dec 2021
Grant
Filling date: 2 Nov 2017 Issue date: 21 Sep 2021
Application
Filling date: 17 May 2019 Issue date: 12 Aug 2021
Wednesday, 18 December 2024
seekingalpha.com
Monday, 9 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Wednesday, 20 November 2024
reuters.com
prnewswire.com
globenewswire.com
Saturday, 9 November 2024
seekingalpha.com
Tuesday, 5 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Thursday, 24 October 2024
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
Monday, 30 September 2024
globenewswire.com
Tuesday, 17 September 2024
globenewswire.com
Friday, 9 August 2024
seekingalpha.com
Thursday, 8 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Friday, 26 July 2024
investorplace.com
Friday, 5 July 2024
globenewswire.com
Monday, 24 June 2024
globenewswire.com
Tuesday, 11 June 2024
businesswire.com
Friday, 7 June 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 14 May 2024
globenewswire.com
Wednesday, 8 May 2024
fool.com
globenewswire.com
Saturday, 4 May 2024
Seeking Alpha
Thursday, 25 April 2024
GlobeNewsWire
Thursday, 22 February 2024
GlobeNewsWire
Tuesday, 20 February 2024
GlobeNewsWire
  • What's the price of Kura Oncology stock today?

    One share of Kura Oncology stock can currently be purchased for approximately $7.33.

  • When is Kura Oncology's next earnings date?

    Unfortunately, Kura Oncology's (KURA) next earnings date is currently unknown.

  • Does Kura Oncology pay dividends?

    No, Kura Oncology does not pay dividends.

  • How much money does Kura Oncology make?

    Kura Oncology has a market capitalization of 686.65M.

  • What is Kura Oncology's stock symbol?

    Kura Oncology, Inc. is traded on the NASDAQ under the ticker symbol "KURA".

  • What is Kura Oncology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Kura Oncology?

    Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Kura Oncology's key executives?

    Kura Oncology's management team includes the following people:

    • Dr. Troy Edward Wilson Chairman, Chief Executive Officer & Pres(age: 56, pay: $1,110,000)
    • Dr. Marc Grasso Chief Financial Officer & Chief Bus. Officer(age: 52, pay: $715,950)
    • Ms. Kathleen Ford Chief Operating Officer(age: 78, pay: $683,400)
    • Ms. Kirsten Flowers Chief Commercial Officer(age: 50, pay: $661,250)
    • Dr. Stephen Dale M.D. Chief Medical Officer(age: 53, pay: $398,930)
  • How many employees does Kura Oncology have?

    As Jul 2024, Kura Oncology employs 142 workers.

  • When Kura Oncology went public?

    Kura Oncology, Inc. is publicly traded company for more then 9 years since IPO on 16 Sep 2015.

  • What is Kura Oncology's official website?

    The official website for Kura Oncology is kuraoncology.com.

  • Where are Kura Oncology's headquarters?

    Kura Oncology is headquartered at 12730 High Bluff Drive, San Diego, CA.

  • How can i contact Kura Oncology?

    Kura Oncology's mailing address is 12730 High Bluff Drive, San Diego, CA and company can be reached via phone at 858 500 8800.

  • What is Kura Oncology stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Kura Oncology in the last 12 months, the avarage price target is $19. The average price target represents a 159.20% change from the last price of $7.33.

Kura Oncology company profile:

Kura Oncology, Inc.

kuraoncology.com
Exchange:

NASDAQ

Full time employees:

142

Industry:

Biotechnology

Sector:

Healthcare

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

12730 High Bluff Drive
San Diego, CA 92130

CIK: 0001422143
ISIN: US50127T1097
CUSIP: 50127T109